LENZ Therapeutics is a company in the advanced stages of clinical development, focused on creating pioneering pharmaceutical products for eye care. The organization's primary effort involves an aceclidine-based eye drop intended to address the decline in near vision associated with presbyopia, a condition affecting nearly two billion individuals worldwide and over 120 million in the US. Situated in San Diego, California, LENZ Therapeutics benefits from the support of prominent venture capital investors.